First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony

BACKGROUND: Current therapies for cutaneous leishmaniasis are limited by poor efficacy, long-term course of treatment, and the development of resistance. We evaluated if pentavalent antimony (an anti-parasitic drug) combined with imiquimod (an immunomodulator) was more effective than pentavalent ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Miranda-Verastegui, Cesar, Tulliano, GianFranco, Gyorkos, Theresa W., Calderon, Wessmark, Rahme, Elham, Ward, Brian, Cruz, Maria, Llanos-Cuentas, Alejandro, Matlashewski, Greg
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2710502/
https://www.ncbi.nlm.nih.gov/pubmed/19636365
http://dx.doi.org/10.1371/journal.pntd.0000491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2710502/
https://www.ncbi.nlm.nih.gov/pubmed/19636365
http://dx.doi.org/10.1371/journal.pntd.0000491

Ejemplares similares